Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	368-370
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.jtho.2020.11.027
Publication status	Published - 1 Mar 2021

Keywords

@article{1911de7ff6f44bda985f3e0b5f6e44fd,

title = "Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC",

keywords = "HIGH-RISK, IMATINIB",

author = "J. Remon and L.E.L. Hendriks",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.jtho.2020.11.027",

language = "English",

volume = "16",

pages = "368--370",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

AU - Remon, J.

AU - Hendriks, L.E.L.

PY - 2021/3/1

Y1 - 2021/3/1

KW - HIGH-RISK

KW - IMATINIB

U2 - 10.1016/j.jtho.2020.11.027

DO - 10.1016/j.jtho.2020.11.027

M3 - Editorial

C2 - 33641720

SN - 1556-0864

VL - 16

SP - 368

EP - 370

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -